"
Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature"
written by A. Prica, A. Pratzer, M. Cheung, K. Thompson, E. Piliotis, N. L. Berinstein, K. Imrie, R. Pradhan, A. Vyas, Z. Ghorab, D. Good, L. Zhang, R. Buckstein,
published by
Journal of Cancer Therapy,
Vol.6 No.1, 2015
has been cited by the following article(s):
[1]
|
Prognostic impact of CD20 expression in adult B-cell acute lymphoblastic leukemia
Clinical Lymphoma Myeloma and Leukemia,
2018
DOI:10.1016/j.clml.2018.02.013
|
|
|